peripheral T cell lymphoma
Conditions
Interventions
Case series:Receive Gemcitabine, Nab-paclitaxel, and Dexamethasone(GAD) chemotherapy
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Signed informed consen; aged 18-75 years; ECOG=0-2;pathological findings were peripheral T cell lymphoma; received chemotherapy or radiation with more than one regimen (anthracycline included), disease progression occurs at the end of chemotherapy (radiation) or during chemotherapy (radiation); There are measurable or/and evaluable lymphoma lesions; No serious organ dysfunction; Compliance with research and visit plans and other programme requirements; women of childbearing age with a negative pregnancy test.
Exclusion criteria
Exclusion criteria: Transformed lymphoma; Participated in other clinical trials in the last 3 months; There is a history of other malignancies secondary to lymphoma, or secondary lymphoma after chemotherapy or radiotherapy,or central invasion of lymphoma; Abnormal laboratory tests: ANC3ULN,Cr>2ULN;active infections, decompensated heart failure, dilated cardiomyopathy that require systemic antibiotic or antiviral therapy, coronary heart disease with depressed ST segment and myocardial infarction, severe organic disease and severe mental disease that have occurred in the last 6 months; Pregnant and lactating women;Treatment for lymphoma was performed within 30 days before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete response rate;progression-free survival;overall survival;safety; | — |
Countries
China
Contacts
Public ContactTongyu LIN
Sun Yat-sen University Cancer Center
Outcome results
None listed